{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "id": "29ndC15xb9V4"
   },
   "outputs": [],
   "source": [
    "# !pip install scispacy\n",
    "# !pip install spacy\n",
    "# !pip install https://s3-us-west-2.amazonaws.com/ai2-s2-scispacy/releases/v0.2.5/en_ner_bc5cdr_md-0.2.5.tar.gz"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {
    "id": "4C7uzNq5GOS3"
   },
   "outputs": [],
   "source": [
    "from collections import Counter, defaultdict\n",
    "import numpy as np\n",
    "import pandas as pd\n",
    "import os\n",
    "\n",
    "# Custom module imports\n",
    "from annotations import Entity, Relation\n",
    "import utils\n",
    "\n",
    "# Visualization imports\n",
    "import matplotlib.pyplot as plt\n",
    "import seaborn as sns\n",
    "sns.set_style('whitegrid')\n",
    "\n",
    "# Spacy imports\n",
    "import scispacy\n",
    "import spacy\n",
    "from spacy import displacy\n",
    "import en_ner_bc5cdr_md"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "DATA_DIR = 'data/'\n",
    "\n",
    "# Loading processed entity - data\n",
    "tags = utils.open_pickle('processed_data/tags')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "7NzA_v-KNobD"
   },
   "source": [
    "### EDA"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {
    "id": "Djq3NYX6IP3G"
   },
   "outputs": [],
   "source": [
    "# Getting counts for different entities\n",
    "entity_counts = defaultdict(int)\n",
    "\n",
    "for entity_dict in tags:\n",
    "    for key, value in entity_dict['entities'].items():\n",
    "        entity_counts[value.name] += 1\n",
    "        \n",
    "# Convert defaultdict to dict\n",
    "entity_counts = dict(entity_counts)\n",
    "\n",
    "# Sort by value\n",
    "entity_counts = {key: value for key, value in sorted(entity_counts.items(), \n",
    "                                                     key = lambda x: x[1], \n",
    "                                                     reverse = True)}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {
    "id": "WQjoXSUjMfqS"
   },
   "outputs": [],
   "source": [
    "# Gettings counts for different relations\n",
    "relation_counts = defaultdict(int)\n",
    "\n",
    "for entity_dict in tags:\n",
    "    for key, value in entity_dict['relations'].items():\n",
    "        relation_counts[value.name] += 1\n",
    "        \n",
    "# Convert defaultdict to dict\n",
    "relation_counts = dict(relation_counts)\n",
    "\n",
    "# Sort by value\n",
    "relation_counts = {key: value for key, value in sorted(relation_counts.items(), \n",
    "                                                       key = lambda x: x[1],\n",
    "                                                       reverse = True)}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 720x432 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "plt.figure(figsize = (10, 6))\n",
    "\n",
    "sns.barplot(x = list(entity_counts.keys()), y = list(entity_counts.values()), \n",
    "            palette = sns.light_palette(\"green\", n_colors = 10, reverse = True))\n",
    "\n",
    "# Annotating counts\n",
    "for i in range(len(entity_counts.values())):\n",
    "    plt.text(x = i - 0.2, y = list(entity_counts.values())[i] + 40, \n",
    "             s = list(entity_counts.values())[i])\n",
    "    \n",
    "# Setting plot title\n",
    "plt.title('Number of occurences of each entity over 303 EHR records', fontsize = 15)\n",
    "plt.savefig('plots/entity_counts.jpg')\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 864x432 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "plt.figure(figsize = (12, 6))\n",
    "\n",
    "sns.barplot(x = list(relation_counts.keys()), y = list(relation_counts.values()), \n",
    "            palette = sns.light_palette(\"green\", n_colors = 10, reverse = True))\n",
    "\n",
    "plt.ylim(0, 8000)\n",
    "\n",
    "# Annotating counts\n",
    "for i in range(len(relation_counts.values())):\n",
    "    plt.text(x = i - 0.2, y = list(relation_counts.values())[i] + 40, \n",
    "             s = list(relation_counts.values())[i])\n",
    "    \n",
    "# Setting plot title\n",
    "plt.title('Number of occurences of entity-relationships over 303 EHR records', fontsize = 15)\n",
    "plt.savefig('plots/relation_counts.jpg')\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "YW8W5prYbo8n"
   },
   "source": [
    "### Scispacy"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {
    "id": "LeENQKybbwrO"
   },
   "outputs": [],
   "source": [
    "nlp = en_ner_bc5cdr_md.load()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {
    "id": "kmQ1_geJcGaM"
   },
   "outputs": [],
   "source": [
    "ehr = []\n",
    "\n",
    "for filename in os.listdir(DATA_DIR):\n",
    "    if filename.endswith(\".txt\"):\n",
    "        f = open(DATA_DIR + filename, 'r')\n",
    "        raw_data = f.read()\n",
    "        ehr.append(raw_data)\n",
    "        f.close()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {
    "id": "kbI0lFRpgir6"
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Admission Date:  [**2114-12-24**]              Discharge Date:   [**2115-1-6**]</br></br>Date of Birth:  [**2070-12-17**]             Sex:   M</br></br>Service: MEDICINE</br></br>\n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Allergies\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ":</br>\n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Heparin\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " Agents</br></br>Attending:[**First Name3 (LF) 943**]</br>Chief Complaint:</br>\n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Hypotension\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " with elevated \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    lactate\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       ", code \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    sepsis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ".</br></br>Major Surgical or Invasive Procedure:</br>Right internal jugular venous catheter placement.</br></br></br>History of Present Illness:</br>44 yoM PMH \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ESRD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " secondary to \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Brights disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " on \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    HD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " s/p two</br>failed renal transplants, HCV, \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    CHF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " with EF 20%, AF on \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    coumadin\n",
       "\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       "who presented to the ED with a two week history of diffuse</br>\n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    abdominal pain\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " with one day of \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    nausea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    vomiting\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " [**2114-12-24**]. Two</br>weeks prior to admission the patient began to experience diffuse</br>dull \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    abdominal pain\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " without \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    nausea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " or \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    vomiting\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " and loose stools</br>2-3 times per day. The patient believed this was secondary to</br>\n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    fluid overload\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ". One week prior to presentation the patient</br>complained of subjective fevers, \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cough\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " productive of yellow</br>sputum. His nephrologist gave him a five-day course of</br>\n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    azithromycin\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       ". The patient had persistent symptoms and was</br>started on \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    levofloxacin\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " by his \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    PCP\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " two days prior to admission.</br>The patient had a history of \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tylenol\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " use 3g/day for 5 days prior</br>to admission for \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    fever\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    body aches\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ". The day prior to admission</br>the patient began to experience worsened \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    abdominal pain\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       "</br>associated with \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    nausea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", a few episodes of \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    vomiting\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ",</br>nonbilious/nonbloody, and \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    diarrhea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " 4-5 times per day, \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    watery\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ",</br>nonbloody.</br>.</br>In the ED the patient was found to be \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    hypotensive\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " with \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    lactate\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       "</br>of 5.6 and a code \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    sepsis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " was called. He was given Vanco, Flagyl</br>and \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Zosyn\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " for presumed \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    infection\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ". He was given Decadron for</br>presumed \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    adrenal insufficiency\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ". He was also given \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Calcium\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       "</br>\n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    gluconate\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    sodium bicarbonate\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       ", Insulin and D50 for \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    hyperkalemia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ".</br>A CVL was placed and he received 3L of NS with normalization of</br>pressures. He was transferred to the MICU.</br>.</br>In the MICU the patient's \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    LFTs\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " were significantly elevated and</br>peaked at ALT 3016, AST 2956, LDH [**2064**], INR 4.3 on [**12-25**]. This</br>was thought to be secondary to \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    shock\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " liver in the setting of</br>\n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    hypotension/sepsis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " versus \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tylenol toxicity\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " despite negative</br>serum \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tylenol\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       ". LFTs subsequently trending down.</br>.</br>Upon transfer to the floor, the patient continues to complain of</br>\n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cough\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " productive of yellow sputum. Denies \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    chest pain\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    shortness\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       "</br>of breath. The patient denied any fevers/chills, \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    abdominal pain\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ",</br>\n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    nausea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    vomiting\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Diarrhea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " improving. Denies dysuria/hematuria;</br>minimal urine output while on HD. Denies lightheadedness. Denies</br>myalgias/arthralgias. Review of systems otherwise negative in</br>detail.</br></br>Past Medical History:</br>1. \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    End-stage renal disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " secondary to \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    glomerulonephritis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " on</br>hemodialysis status post two failed transplants [**2089**] and [**2097**]</br>2. \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Coronary artery disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " status post \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    myocardial infarction\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " and</br>stent [**2105**]</br>3. \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Congestive heart failure\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " with ejection fraction 10%, status</br>post right sided placement of ICD</br>4. \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Cerebrovascular accident\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " [**2105**] without residual complications</br>or deficits</br>5. \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Atrial fibrillation\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       "</br>6. \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Hypertension\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       "</br>7. Basal cell and squamous cell skin cancers status post</br>excision and radiation to lower face</br>8. \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Gout\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       "</br>9. \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Erectile dysfunction\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       "</br>10. \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Right lung pneumonia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " with \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    pleurisy\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       "</br>11. \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Hepatitis C\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", genotype 2</br></br>Social History:</br>He is married, lives in [**Location 13011**] with wife of 11 years, son and</br>daughter. [**Name (NI) **] owns and runs a landscaping/contracting business</br>and works for the city sanding the streets during the winter. He</br>denies tobacco or recreational drug use.</br></br>Family History:</br>Mother, maternal uncle, and grandfather with [**Name2 (NI) **]</br>grandmother, \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Lymphoma\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " in paternal grandfather, peripheral</br>vascular disease in maternal grandmother, no h/o \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    kidney disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ",</br>other CA, \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    heart disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    CVA\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", or \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    psychiatric diseases\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ".</br></br>Physical Exam:</br>VITAL SIGNS: 98.6 112/68 130 18 98RA</br>GENERAL: \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    NAD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       ", pleasant and cooperative.</br>\n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    HEENT\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       ": PERRL, EOMI, \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    OP\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " clear, MMM, anicteric sclerae</br>NECK: no masses, no LAD, no JVD, no carotid bruit, RIJ in place</br></br>HEART: \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    irreg irreg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", nl s1s2, \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    holosystolic murmur [**3-5*\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       "*] over</br>\n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    precordium\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", laterally displaced PMI, no rub</br>\n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    LUNGS\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       ": cta b/l, no crackles or \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    wheezes\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ".</br>ABDOMEN: soft, nd, +bs, no \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    organomegaly\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", tender in RLQ, negative</br>[**Doctor Last Name **] sign, no rebound, no guarding</br>EXTREMITIES: no \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cyanosis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", no \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    clubbing\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       "; no \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    edema\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", 1+ dp, pulses</br>b/l.</br>NEUROLOGIC: awake, alert, a&amp;ox3, cn ii-xii intact; strength 5/5</br>bilaterally, sensory and coordination grossly intact, reflesxes</br>1+ bilaterally</br>SKIN: \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    petechia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " on trunk, \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    AV fistula\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " in L arm, positive thrill</br></br></br>Pertinent Results:</br>Labwork on admission:</br>[**2114-12-24**] 12:15PM   WBC-14.0*# RBC-3.54* HGB-11.5* HCT-34.7*</br>MCV-98 MCH-32.5* MCHC-33.2 RDW-14.6</br>[**2114-12-24**] 12:15PM   PLT COUNT-286</br>[**2114-12-24**] 12:15PM   NEUTS-77.9* LYMPHS-14.1* MONOS-6.7 EOS-0.2</br>BASOS-1.1</br>[**2114-12-24**] 12:15PM   PT-23.1* PTT-29.9 INR(PT)-2.3*</br>[**2114-12-24**] 12:15PM   GLUCOSE-62* UREA N-90* CREAT-14.8*#</br>SODIUM-139 POTASSIUM-7.1* CHLORIDE-86* TOTAL CO2-23 ANION</br>GAP-37*</br>[**2114-12-24**] 12:15PM   ALT(SGPT)-1122* AST(SGOT)-1469* LD(LDH)-1523*</br>ALK PHOS-156* AMYLASE-59 TOT BILI-1.5</br>[**2114-12-24**] 12:15PM   LIPASE-43</br>[**2114-12-24**] 12:15PM   \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ALBUMIN-4.0\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " CALCIUM-10.7* PHOSPHATE-11.2*#</br>\n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    MAGNESIUM-2.8*\n",
       "[**2114-12-24**] 12:15PM   CORTISOL-36.0*\n",
       "[**2114-12-24**] 12:27PM   \n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       "LACTATE-5.9*</br>.</br>CHEST (PA &amp; LAT)  [**2114-12-24**]</br>IMPRESSION:</br>Clear lungs, mild \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    pulmonary congestion\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cardiomegaly\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ",</br>unchanged.</br>.</br>CT \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ABD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " W&amp;W/O C  [**2114-12-25**]</br>IMPRESSION:</br>1) \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Cardiomegaly\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    hepatomegaly\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " with \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    abnormal liver perfusion\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       "</br>likely secondary to passive congestion (nutmeg liver). No focal</br>hepatic abscess or adjacent \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    hematoma\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ".</br>2) \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Cholelithiasis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " and sludge/vicarious excretion of IV contrast.</br>Small amount of pericholecystic fluid is present. The fluid</br>could be due to patient's liver dysfunction/third spacing from</br>\n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    CHF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ". If \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cholecystitis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " is of clinical concern, \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    HIDA\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " scan can be</br>performed provided the total \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    bilirubin\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " is not elevated.</br>3) Hyperdense renal cortex in left lower quadrant transplanted</br>kidney. Findings are most likely due to chronic rejection or</br>prior \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ATN\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ". There is apparent thickening of the arterial wall</br>supplying the transplant. No \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    hydronephrosis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " or perinephric</br>collection.</br>4) Minor anatomic variant involving liver vasculature as</br>described above. Hepatic veins and portal venous system appear</br>widely patent.</br>5) 6 mm lesion in head of pancreas. Continued follow up of this</br>area is recommended on future studies.</br>6) Areas of ground glass \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    opacity\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " and intralobular septal</br>thickening in the lung bases, most likely due to fluid</br>overload/CHF. Nodular areas of \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    opacity\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " are also present which</br>could be due to \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    infection\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ". Continued followup is reccomended.</br>7) Small lymph nodes and vague retroperitoneal stranding.</br>Findings could be due to \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    CHF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ".</br>.</br>ECG Study Date of [**2114-12-25**]  2:41:34 AM</br>\n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Atrial fibrillation\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " with rapid ventricular response</br>Intraventricular conduction delay - possible atypical left</br>\n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    bundle branch block\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       "</br>Anterior \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    myocardial infarct\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", age indeterminate - may be old</br>Nonspecific ST-T wave changes</br>Since previous tracing of [**2114-2-7**], ventricular rate faster</br>.</br>ECHO Study Date of [**2114-12-28**]</br>Conclusions:</br>1. The left atrium is moderately dilated.</br>2. The left ventricular cavity is severely dilated. There is</br>severe \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    global left ventricular hypokinesis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ". Overall left</br>ventricular systolic function is severely \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    depressed\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ". Left</br>ventricular dysnchrony is present.</br>3. The right ventricular cavity is dilated. Right ventricular</br>systolic</br>function appears \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    depressed\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ".</br>4. The aortic valve leaflets are mildly thickened. Mild (1+)</br>aortic</br>regurgitation is seen.</br>5. The mitral valve leaflets are mildly thickened. Moderate to</br>severe (3+) \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    mitral regurgitation\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " is seen. The effective</br>regurgitant orifice is &gt;=0.40cm2</br>6. Moderate [2+] tricuspid regurgitation is seen. There is</br>moderate \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    pulmonary artery systolic hypertension\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ".</br>7. There is a trivial/physiologic \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    pericardial effusion\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ".</br>8. Compared with the report of the prior study of [**2114-1-8**], LV</br>function is probably worse.</br>.</br>CHEST (PA &amp; LAT)  [**2114-12-29**]</br>IMPRESSION: Evidence for \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    pulmonary venous hypertension\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ".</br>\n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Cardiomegaly\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ". No focal consolidation.</br>.</br>Labwork on discharge:</br>[**2115-1-6**] 06:30AM</br>COMPLETE BLOOD COUNT</br>White Blood Cells 8.7 K/uL 4.0 - 11.0</br>Red Blood Cells 2.74* m/uL 4.6 - 6.2</br>Hemoglobin 9.7* g/dL 14.0 - 18.0</br>Hematocrit 29.3* % 40 - 52</br>MCV 107* fL 82 - 98</br>MCH 35.6* pg 27 - 32</br>MCHC 33.3 % 31 - 35</br>RDW 18.1* % 10.5 - 15.5</br>BASIC COAGULATION (PT, PTT, PLT, INR)</br>Platelet Count 128* K/uL 150 - 440</br>[**2115-1-6**] 06:30AM</br>RENAL &amp; GLUCOSE</br>\n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Glucose\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 121* mg/dL 70 - 105</br>Urea Nitrogen 56* mg/dL 6 - 20</br>\n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Creatinine\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 7.5*# mg/dL 0.5 - 1.2</br>\n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Sodium\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 138 \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    mEq/L 133 - 145\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       "</br>\n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Potassium\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 3.8 mEq/L 3.3 - 5.1</br>Chloride 99 mEq/L 96 - 108</br>Bicarbonate 27 mEq/L 22 - 32</br>Anion Gap 16 mEq/L 8 - 20</br>ENZYMES &amp; BILIRUBIN</br>\n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alanine\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " Aminotransferase (ALT) 146* IU/L 0 - 40</br>Asparate Aminotransferase (AST) 45* IU/L 0 - 40</br>Lactate Dehydrogenase (LD) 274* IU/L 94 - 250</br>Alkaline Phosphatase 151* IU/L 39 - 117</br>\n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Bilirubin\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       ", Total 1.6* mg/dL 0 - 1.5</br>CHEMISTRY</br>Albumin 3.1* g/dL 3.4 - 4.8</br>\n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Calcium\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       ", Total 7.4* mg/dL 8.4 - 10.2</br>Phosphate 4.1 mg/dL 2.7 - 4.5</br>\n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Magnesium\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 2.2 mg/dL 1.6 - 2.6</br>[**2115-1-6**] 06:30AM</br>RENAL &amp; GLUCOSE</br>\n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Glucose\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 121* mg/dL 70 - 105</br>Urea Nitrogen 56* mg/dL 6 - 20</br>\n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Creatinine\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 7.5*# mg/dL 0.5 - 1.2</br>\n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Sodium\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 138 \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    mEq/L 133 - 145\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       "</br>\n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Potassium\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 3.8 mEq/L 3.3 - 5.1</br>Chloride 99 mEq/L 96 - 108</br>Bicarbonate 27 mEq/L 22 - 32</br>Anion Gap 16 mEq/L 8 - 20</br>ENZYMES &amp; BILIRUBIN</br>\n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alanine\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " Aminotransferase (ALT) 146* IU/L 0 - 40</br>Asparate Aminotransferase (AST) 45* IU/L 0 - 40</br>Lactate Dehydrogenase (LD) 274* IU/L 94 - 250</br>Alkaline Phosphatase 151* IU/L 39 - 117</br>\n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Bilirubin\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       ", Total 1.6* mg/dL 0 - 1.5</br>CHEMISTRY</br>Albumin 3.1* g/dL 3.4 - 4.8</br>\n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Calcium\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       ", Total 7.4* mg/dL 8.4 - 10.2</br>Phosphate 4.1 mg/dL 2.7 - 4.5</br>\n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Magnesium\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 2.2 mg/dL 1.6 - 2.6</br>[**2115-1-6**] 10:29AM</br>BASIC COAGULATION (PT, PTT, PLT, INR)</br>PT 27.9* sec 10.4 - 13.1</br>PTT 47.7* sec 22.0 - 35.0</br>INR(PT) 2.9*   0.9 - 1.1</br></br>Brief Hospital Course:</br>44 year-old male with past medical history of \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ESRD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " on \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    HD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", HCV,</br>presenting with \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    hypotension\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " and elevated \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    lactate\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       ", presumed</br>\n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    sepsis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " without source found. The patient was noted to have</br>elevated LFTs on admission. The patient was found to be \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    HIT\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " Ab</br>positive.</br>.</br>1. \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Sepsis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ": There was no source found, but patient had received</br>antibiotics prior to admission. The patient remained afebrile</br>and hemodynamically stable throughout transfer to the floor. The</br>patient had \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    leukocytosis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " on admission but this resolved prior to</br>transfer. The patient completed an empiric seven-day course of</br>vancomycin/zosyn and ten-day course of flagyl. The patient's</br>immunosuppressive therapy with \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cyclosporine\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " for history of renal</br>transplant was discontinued; \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    prednisone\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 10 mg \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    QOD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " was continued.</br>CXR x 2 without evidence of \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    pneumonia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ". The patient's blood,</br>urine, stools, and sputum cultures were negative at the time of</br>discharge. C. difficile toxin B was negative. The patient</br>complained of continued \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cough\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " and loose stools which were</br>improving prior to discharge.</br>.</br>2. \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Hypotension\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ": Resolved prior to transfer to the floor. Likely</br>\n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    sepsis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " given elevated \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    lactate\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Hypovolemia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " possible in setting</br>of poor po prior to admission. Cardiac etiology unlikely; no</br>significant change in cardiac function and cardiac enzymes</br>unrevealing. \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Adrenal insufficiency\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " was unlikely with random</br>\n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cortisol\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " of 36,  however, the patient on chronic \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    steroids\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       "; the</br>patient was continued on \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    prednisone\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 10 mg every other day for</br>history of renal transplant. The patient received treatment for</br>\n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    sepsis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " as above.</br>.</br>3. Elevated \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    LFTs/coagulopathy\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       ": Secondary to \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    shock\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " liver versus</br>\n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tylenol toxicity\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       ". The patient was initially maintained on</br>mucomyst gtt but this was discontinued when the patient's liver</br>function tests improved. There was likely a component of</br>congestion secondary to \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    CHF\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ". This was unlikely secondary to HCV</br>as there was no change in immunosuppression and only mild active</br>\n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    inflammation\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " on very recent biopsy. Unlikely to be due to recent</br>liver biopsy. The patient's liver function tests continued to</br>trend down prior to discharge.</br>.</br>4. \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Atrial fibrillation\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ": The patient's \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    coumadin\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " was initially</br>held in the setting of \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    liver failure\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " and elevated INR. The</br>patient's \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    digoxin\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    amiodarone\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " were initially held in the</br>setting of \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    renal and liver failure\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " and the patient's rate was</br>subsequently \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    poorly-controlled\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " to heart rate 130-140s. The</br>patient was followed by his primary cardiologist, Dr. [**Last Name (STitle) 911**],</br>during admission. The patient's \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    amiodarone\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " was restarted and</br>increased from previous per his recommendations. \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Digoxin\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " was not</br>restarted. The patient's elanopril was discontinued on admission</br>and the patient was started on \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    captopril\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       "; there was an attempt</br>to \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    up-titrate\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " the dose but the patient's blood pressure did not</br>tolerate the increase. The patient was discharged on \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    captopril\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       "</br>6.25 twice daily. The patient's blood pressure does not tolerate</br>\n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    beta-blocker\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " therapy. The patient was restarted on \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    coumadin\n",
       "\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       "prior to discharge. The patient's rapid ventricular rate is most</br>likely compensatory for low ejection fraction; rate control to</br>110-120s is acceptable. The patient's rate was at goal 110s-120s</br>on discharge. The patient will follow-up with Dr. [**Last Name (STitle) 911**] as an</br>outpatient.</br>.</br>5. Acute on \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    chronic renal failure\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ": Baseline \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    creatinine\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " [**5-2**]. The</br>patient is on HD status post two failed renal transplants. The</br>differential for the patient's \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    acute renal failure\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " included</br>acute tubular necrosis and cyclotoxicity (recently on</br>\n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    azithromycin\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       "). The patient's ACE inhibitor was initially held.</br>The patient's \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    creatinine\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " did not improve to baseline and was 7.5</br>prior to discharge. The patient was followed by the renal</br>service throughout hospitalization. The patient continued to</br>receive hemodialysis per his MWF schedule. The patient was</br>started on sensipar for elevated PTH. The patient was continued</br>on \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    prednisone\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 10 mg \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    QOD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " for history of renal transplant. The</br>patient's \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cyclosporine\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " was discontinued. Amphogel was</br>discontinued and cinecalcet was added to the patient's regimen.</br>.</br>6. Thrombocytopenia/HIT Ab positive: \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    HIT\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " antibodies were sent</br>because of the patient's \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    thrombocytopenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ". The patient's \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    HIT\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       "</br>antibodies were positive. The patient had been on \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    heparin\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " SC and</br>\n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    heparin\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " flushes in the MICU but these were discontinued prior to</br>transfer to the floor. The patient was followed by hematology</br>during admission. The patient had a right basilic vein</br>\n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    thrombosis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " visualized but no other signs or symptoms of</br>\n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    thrombosis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ". After discussion with hematology and pharmacy, the</br>patient was started on \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    argatroban\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " and bridged to \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    coumadin\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       ". The</br>patient's INR goal was 2.5-3.5 given his history of \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    liver\n",
       "disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ".</br>.</br>7. \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Congestive heart failure\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ". EF of 10% per echo [**12-28**] with 3+ MR,</br>2+ TR. Mixed ischemic/nonischemic dilated cardiomyopathy.</br>Patient has a fixed \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    LAD/anterior defect\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " on MIBI on 2/[**2114**]. The</br>patient is status post ICD placement [**1-1**]. The patient was</br>started on \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    captopril\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " as above. The patient's blood pressure does</br>not tolerate \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    beta-blocker\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " therapy. The patient's volume status</br>was addressed at hemodialysis. The patient was assessed for</br>biventricular ICD by \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    EP\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       "; the decision was made not to place at</br>this time given the patient's narrow QRS duration and especially</br>in the setting of recent \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    sepsis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ". The patient will follow-up with</br>Drs. [**Last Name (STitle) 911**] and [**Name5 (PTitle) 437**] in [**5-3**] weeks. The patient will receive</br>outpatient cardiopulmonary assessment for possible cardiac</br>transplant.</br>.</br>8. \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Coronary artery disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " status post \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    myocardial infarction\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " and</br>stent [**2105**]. The patient was without complaints of \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    chest pain\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       "</br>throughout admission. The patient was continued on \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    aspirin\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       ". The</br>patient's elanopril was discontinued and the patient was started</br>on \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    captopril\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " as above. The patient's blood pressure does not</br>tolerate \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    beta-blocker\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " therapy.</br>.</br>9. Nucleated red blood cells. There were 20 NRBC/100 white blood</br>cells on the patient's blood smear on transfer to the floor,</br>with low grade \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    hemolysis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " and high reticulocyte count. Hematology</br>was consulted and believed this was likely secondary to</br>\n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    hyperactive\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " marrow stimulated in the setting of recent \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    sepsis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ".</br>This resolved prior to discharge.</br></br>Medications on Admission:</br>\n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Prednisone\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 10 mg PO \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    QOD\n",
       "B Complex-Vitamin C-Folic Acid 1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " mg PO DAILY</br>\n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Aspirin\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 81 mg Tablet PO DAILY</br>\n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Coumadin\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 1 mg PO DAILY</br>\n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Amiodarone\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 100 mg [**Hospital1 **]</br>\n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Cyclosporine\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       "</br>\n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Amphogel\n",
       "\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       "\n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Elanopril\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       "</br></br></br>Discharge Medications:</br>1. \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Captopril\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 12.5 mg Tablet Sig: 0.5 Tablet PO BID (2 times a</br>day).</br>Disp:*30 Tablet(s)* Refills:*2*</br>2. \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Prednisone\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 10 mg Tablet Sig: One (1) Tablet PO \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    QOD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " ().</br>3. B Complex-Vitamin C-Folic Acid 1 mg Capsule Sig: One (1) Cap</br>PO DAILY (Daily).</br>4. \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Aspirin\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 81 mg Tablet, Chewable Sig: One (1) Tablet, Chewable</br>PO DAILY (Daily).</br>5. \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Cinacalcet\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 30 mg Tablet Sig: One (1) Tablet PO DAILY (Daily).</br>Disp:*30 Tablet(s)* Refills:*2*</br>6. \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Amiodarone\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 200 mg Tablet Sig: One (1) Tablet PO DAILY</br>(Daily).</br>Disp:*30 Tablet(s)* Refills:*2*</br>7. \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Lanthanum\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 500 mg Tablet, Chewable Sig: One (1) Tablet,</br>Chewable PO TID W/MEALS (3 TIMES A DAY WITH MEALS).</br>\n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Disp:*90\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " Tablet, Chewable(s)* Refills:*2*</br>8. \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Pantoprazole\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 40 mg Tablet, Delayed Release (E.C.) Sig: One</br>(1) Tablet, Delayed Release (E.C.) PO Q24H (every 24 hours).</br>Disp:*30 Tablet, Delayed Release (E.C.)(s)* Refills:*2*</br>9. \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Coumadin\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 1 mg Tablet Sig: Two (2) Tablet PO at bedtime.</br>Disp:*60 Tablet(s)* Refills:*2*</br>10. \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Oxycodone\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 5 mg Tablet Sig: One (1) Tablet PO Q8H (every 8</br>hours) as needed for \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    abdominal pain\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ".</br>Disp:*20 Tablet(s)* Refills:*0*</br></br></br>Discharge Disposition:</br>Home</br></br>Discharge Diagnosis:</br>Primary:</br>1. \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Sepsis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       "</br>2. Shock liver</br>3. \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Heparin-induced thrombocytopenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       "</br>.</br>Secondary:</br>1. \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    End-stage renal disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " on hemodialysis</br>2. \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Coronary artery disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " status post \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    myocardial infarction\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " and</br>stent [**2105**]</br>3. \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Congestive heart failure\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " with ejection fraction 10%, status</br>post right sided placement of ICD</br>4. \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Cerebrovascular accident\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " [**2105**] without residual complications</br>or deficits</br>5. \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Atrial fibrillation\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       "</br>6. \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Hypertension\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       "</br>7. Basal cell and squamous cell skin cancers status post</br>excision and radiation to lower face</br>8. \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Gout\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       "</br>9. \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Erectile dysfunction\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       "</br>10. \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Right lung pneumonia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       " with \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    pleurisy\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       "</br>11. \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Hepatitis C\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", genotype 2</br></br></br>Discharge Condition:</br>Afebrile, vital signs stable.</br></br></br>Discharge Instructions:</br>Please contact a physician if you experience \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    fevers\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    chills\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ",</br>\n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    abdominal pain\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    nausea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    vomiting\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    diarhea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ", black stools or blood</br>in your stools, or any other concerning symptoms.</br>.</br>Please take your medications as prescribed.</br>- You \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cyclosporine\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " was discontinued for now; you will restart at</br>outpatient dialysis per Dr. [**Last Name (STitle) 1860**].</br>- Your amphogel was discontinued.</br>- Your elanopril was discontined.</br>- You should take \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    captopril\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 6.25 mg twice daily to control your</br>heart rate.</br>- Your \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    amiodarone\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " was increased to 200 mg once daily.</br>- You should take fosrenal 500 mg three times daily with meals</br>to control \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    phosphorus\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " because of \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    kidney failure\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ".</br>- You should take cinecalcet 30 mg once daily to control \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    calcium\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       "</br>and \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    phosphorus\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " because of \n",
       "<mark class=\"entity\" style=\"background: #D7BDE2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    kidney failure\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">DISEASE</span>\n",
       "</mark>\n",
       ".</br>- You should take protonix 40 mg once daily to protect your</br>stomach when taking \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    prednisone\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       ".</br>- You should take \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    coumadin\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " 2 mg once daily and follow-up in</br>\n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    coumadin\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " clinic on Monday.</br>.</br>Please keep your appointments as below.</br></br>Followup Instructions:</br>Please follow-up in \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    coumadin\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " clinic on Monday regarding your INR</br>levels.</br>.</br>The office of Drs. [**Last Name (STitle) 911**] and [**Name5 (PTitle) 437**] should contact you regarding</br>follow-up appointments. Please contact \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Dr.[**Name\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " (NI) 5786**] office at</br>([**Telephone/Fax (1) 7236**] or \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Dr.[**Name\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " (NI) 3536**] office at ([**Telephone/Fax (1) 13786**] if you do</br>not hear from their representatives or have any questions.</br>.</br>Follow-up with your nephrologist: Provider: [**First Name8 (NamePattern2) **] [**Name11 (NameIs) **], [**Name Initial (NameIs) **].D.,</br>\n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    PH.D.[**MD Number(3) 708**]:[**Telephone/Fax\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " (1) 435**] Date/Time:[**2115-1-7**] 2:00</br>.</br>[**Month/Day/Year **] test for heart transplant evaluation: Provider: [**Name10 (NameIs) 10081**]</br>TESTING Phone:[**Telephone/Fax (1) 1566**] Date/Time:[**2115-1-14**] 1:15</br>.</br>Follow-up with your primary care doctor, Dr. [**Last Name (STitle) 14757**] [**Name (STitle) 13674**], on</br>[**1-17**] at 5:30pm. Please call [**Telephone/Fax (1) 14758**] if you need to</br>reschedule.</br>.</br>Provider:  [**Name10 (NameIs) 676**] CLINIC Phone:[**Telephone/Fax (1) 59**] Date/Time:[**2115-4-16**]</br>3:30</br>Provider: [**Known firstname **] [**Last Name (NamePattern4) 1008**], M.D. \n",
       "<mark class=\"entity\" style=\"background: #F9E79F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Phone:[**Telephone/Fax\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">CHEMICAL</span>\n",
       "</mark>\n",
       " (1) 285**]\n",
       "Date/Time:[**2115-4-16**] 4:00\n",
       "\n",
       "\n",
       "\n",
       "</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "doc = nlp(ehr[0])\n",
    "\n",
    "colors = {\"DISEASE\":\"#D7BDE2\", \"CHEMICAL\":\"#F9E79F\"}\n",
    "options = {\"ents\":[\"DISEASE\", \"CHEMICAL\"], \"colors\":colors}\n",
    "displacy.render(doc, style = \"ent\", jupyter=True, options = options)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Custom-built entity highlighter"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "ehr = utils.open_pickle(\"processed_data/ehr\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Drug&nbsp;</span>&nbsp&nbsp&nbsp&nbsp&nbsp<span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;Strength&nbsp;</span>&nbsp&nbsp&nbsp&nbsp&nbsp<span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Form&nbsp;</span>&nbsp&nbsp&nbsp&nbsp&nbsp<span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;Frequency&nbsp;</span>&nbsp&nbsp&nbsp&nbsp&nbsp<span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;Route&nbsp;</span>&nbsp&nbsp&nbsp&nbsp&nbsp<span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;Dosage&nbsp;</span>&nbsp&nbsp&nbsp&nbsp&nbsp<span style = \"background-color: #e4e7d2; border-radius: 5px;\">&nbsp;Reason&nbsp;</span>&nbsp&nbsp&nbsp&nbsp&nbsp<span style = \"background-color: #ff8197; border-radius: 5px;\">&nbsp;ADE&nbsp;</span>&nbsp&nbsp&nbsp&nbsp&nbsp<span style = \"background-color: #97c4f5; border-radius: 5px;\">&nbsp;Duration&nbsp;</span>&nbsp&nbsp&nbsp&nbsp&nbsp<br>----------------------------------------------------------------------------------------------------<br><br>Admission Date:  [**2181-9-8**]              Discharge Date:   [**2181-9-26**]<br><br>Date of Birth:  [**2119-11-6**]             Sex:   M<br><br>Service: MEDICINE<br><br>Allergies:<br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Penicillins&nbsp;</span><br><br>Attending:[**First Name3 (LF) 330**]<br>Chief Complaint:<br>productive cough, shortness of breath<br><br>Major Surgical or Invasive Procedure:<br>Placement of PICC line<br><br><br>History of Present Illness:<br>61 y/o male with history of right lung Non Small Cell Cancer,<br>s/p right upper lobe lobectomy, severe COPD, and a history of<br>MRSA and psuedomanous PNA who presents from ED to ICU with<br>hypoxia and possible PNA. He recently had a 3 week<br>hospitalization for COPD exacerbation and treated for a<br><span style = \"background-color: #e4e7d2; border-radius: 5px;\">&nbsp;pneumonia&nbsp;</span> with <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Bactrim&nbsp;</span> (for <span style = \"background-color: #e4e7d2; border-radius: 5px;\">&nbsp;MRSA&nbsp;</span>) and <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;levaquin&nbsp;</span> (for<br><span style = \"background-color: #e4e7d2; border-radius: 5px;\">&nbsp;pseudomonas&nbsp;</span>). He was discharged on [**8-6**] but continued to feel<br>SOB and was readmitted several days later where he grew out<br>pseudomonas Resistant to <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;ciprofloxacin&nbsp;</span>. Workup also included a<br>CXR which showed a question of interstitial process and CTA was<br>negative for PE but did reveal bilateral patchy infiltrates in<br>middle and lower lobes bilaterally c/w <span style = \"background-color: #e4e7d2; border-radius: 5px;\">&nbsp;pneumonia&nbsp;</span>. Pt was treated<br>with <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;vancomycin&nbsp;</span> and <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;ceftaz&nbsp;</span> during this hospital course, and was<br>discharged on <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;prednisone&nbsp;</span> <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;taper&nbsp;</span>.<br>.<br>He was doing well at home until 1 week PTA when he reports onset<br>of fevers to 101, weakness, SOB, pleuritic CP, cough. Denies any<br>arm or jaw pain, diaphoresis, nausea, palpitations. ROS + for<br>photophobia, dizziness with some balance loss, but no loss of<br>consciousness over this time period as well.<br>Pt therefore presented to [**Hospital **] hospital. He remained clinically<br>stable throughout his course at MVH - afebrile, BP<br>110s-130s/60s-70s, HR 60s-80s, RR 18-24 and sats of 93% on 3L -><br>93% on 2L. His pulmonologist (Dr. [**Last Name (STitle) 14069**] was contact[**Name (NI) **] and<br>recommended transfer to [**Hospital1 18**] for possible bronchoscopy to<br>figure out why he is having recurrent COPD flares.<br>On arrival here, he states that his breathing feels comfortable.<br><br><br>Past Medical History:<br>1. Non-small cell lung cancer, s/p R upper lobectomy, partial R<br>fifth rib resection c/b chronic pain. No <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;chemo&nbsp;</span> or radiation.<br>2. COPD w/ severely reduced DLCO, FEV1, and FEV1/FVC ratio<br>3. h/o MRSA and pseudomonas PNA<br>4  UC - s/p multiple surgeries, most recently in late 80s. S/P<br>total colectomy and ileostomy<br>5. <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Steroid&nbsp;</span> induced <span style = \"background-color: #ff8197; border-radius: 5px;\">&nbsp;hyperglycemia&nbsp;</span><br>6. PFO<br>7. h/o cardiomegaly<br>8. h/o depression<br><br><br>Social History:<br>Married, 2 daughters, lives on the [**Name (NI) **].  Not current<br>smoker, quit in [**2177**] w/ dx of lung cancer, 40 pack-yr history.<br>Occasional EtOH use. Worked as a paiting contractor, retired<br>after lung cancer surgery.<br><br><br>Family History:<br>F died of lung cancer; M died of Alzheimer's. Has 3 sisters, all<br>older than him, healthy<br><br><br>Physical Exam:<br>Vitals - T 95.9, HR 95, BP 107/58, RR 20, O2 97% on high flow<br>face mask<br>General - awake alert, sitting up in bed, mask on, NAD<br>HEENT - PERRL, EOMI, dry MM<br>CVS - slightly tachycardic, no noted m/r/g<br>Lungs - diffuse insp and exp wheezes, scattered coarse rhonci at<br>bases, bronchial breath sounds on right middle airfield<br>Abd - tense, non-tender, ileostomy in place<br>Ext - no LE edema b/l<br><br><br>Pertinent Results:<br>ADMISSION LABS:<br>[**2181-9-8**] 10:15PM BLOOD WBC-9.3 RBC-3.40* Hgb-10.0* Hct-28.8*<br>MCV-85 MCH-29.4 MCHC-34.6 RDW-15.4 Plt Ct-280#<br>[**2181-9-8**] 10:15PM BLOOD Neuts-80* Bands-10* Lymphs-3* Monos-6<br>Eos-0 Baso-0 Atyps-0 Metas-1* Myelos-0 NRBC-1*<br>[**2181-9-8**] 10:15PM BLOOD PT-16.1* PTT-31.4 INR(PT)-1.5*<br>[**2181-9-8**] 10:15PM BLOOD Glucose-262* UreaN-65* Creat-2.8*#<br>Na-129* K-4.1 Cl-87* HCO3-24 AnGap-22*<br>[**2181-9-9**] 05:39AM BLOOD ALT-122* AST-155* LD(LDH)-347*<br>AlkPhos-118* Amylase-64 TotBili-0.5<br>[**2181-9-10**] 05:10AM BLOOD ALT-79* AST-52* LD(LDH)-311* AlkPhos-115<br>TotBili-0.4<br>[**2181-9-13**] 04:14AM BLOOD ALT-14 AST-1 LD(LDH)-255* AlkPhos-108<br>TotBili-0.3<br>[**2181-9-9**] 05:39AM BLOOD Lipase-12<br>[**2181-9-10**] 05:10AM BLOOD Lipase-13<br>[**2181-9-9**] 05:39AM BLOOD Albumin-2.5* Calcium-7.7* Phos-6.6*#<br>Mg-2.1<br>[**2181-9-13**] 04:14AM BLOOD calTIBC-160* Ferritn-1317* TRF-123*<br>[**2181-9-9**] 08:26AM BLOOD HBsAg-NEGATIVE HBsAb-NEGATIVE IgM<br>HBc-NEGATIVE IgM HAV-NEGATIVE<br>[**2181-9-9**] 08:26AM BLOOD HCV Ab-NEGATIVE<br>[**2181-9-9**] 01:59AM BLOOD Type-ART pO2-110* pCO2-40 pH-7.38<br>calTCO2-25 Base XS-0 Intubat-NOT INTUBA<br>[**2181-9-8**] 10:31PM BLOOD Lactate-2.4*<br>Pertinent Labs/Studies:<br>.<br>CHEST (PORTABLE AP)  [**2181-9-8**] 10:10 PM<br>IMPRESSION:<br>1. New right middle lung opacification most consistent with<br>newly developing pneumonia given acuity of onset (1 month).<br>2. Underlying chronic obstructive pulmonary disease, status post<br>right thoracotomy.<br>.<br>[**2181-9-24**]: Portable CXR -<br>IMPRESSION:<br>Minimal worsening of right pneumonia, superimposed upon severe<br>emphysema.  It is difficult to exclude a component of<br>necrotizing infection.<br>Persistent air collection at right apex, likely due to a<br>postoperative<br>pneumothorax, unchanged since recent radiograph, but worse when<br>compared to older studies from [**2181-7-20**].<br>.<br>[**2181-9-11**]: Echocardiogram<br>Conclusions:<br>1. The left ventricular cavity size is normal. Overall left<br>ventricular<br>systolic function cannot be reliably assessed.<br>2. The mitral valve leaflets are mildly thickened. The mitral<br>valve is not well seen.<br>3. There is no obvious vegetations seen, but the cardiac valves<br>are not well seen.<br>.<br>.<br>MICROBIOLOGY:<br>[**2181-9-9**] SPUTUM  Source: Expectorated.<br>GRAM STAIN (Final [**2181-9-9**]):<br>      >25 PMNs and <10 epithelial cells/100X field.<br>      4+   (>10 per 1000X FIELD):   GRAM POSITIVE COCCI.<br>                                    IN PAIRS AND CLUSTERS.<br>      1+    (<1 per 1000X FIELD):   BUDDING YEAST.<br>      1+    (<1 per 1000X FIELD):   GRAM NEGATIVE DIPLOCOCCI.<br><br>   RESPIRATORY CULTURE (Final [**2181-9-13**]):<br>      OROPHARYNGEAL FLORA ABSENT.<br>      STAPH AUREUS COAG +    MODERATE GROWTH.<br>      PSEUDOMONAS AERUGINOSA.    SPARSE GROWTH.<br>      YEAST.    SPARSE GROWTH.<br><br>                              SENSITIVITIES: MIC expressed in<br>MCG/ML<br><br>_________________________________________________________<br>                             STAPH AUREUS COAG +<br>                             |          PSEUDOMONAS AERUGINOSA<br>                             |          |<br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;CEFEPIME&nbsp;</span>--------------                2 S<br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;CEFTAZIDIME&nbsp;</span>-----------                4 S<br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;CIPROFLOXACIN&nbsp;</span>---------              =>4 R<br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;ERYTHROMYCIN&nbsp;</span>----------   =>8 R<br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;GENTAMICIN&nbsp;</span>------------ <=0.5 S     =>16 R<br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;IMIPENEM&nbsp;</span>--------------                8 I<br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;LEVOFLOXACIN&nbsp;</span>----------   =>8 R<br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;MEROPENEM&nbsp;</span>-------------                8 I<br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;OXACILLIN&nbsp;</span>-------------   =>4 R<br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;PENICILLIN&nbsp;</span>------------ =>0.5 R<br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;PIPERACILLIN&nbsp;</span>----------                8 S<br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;PIPERACILLIN/TAZO&nbsp;</span>-----                8 S<br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;RIFAMPIN&nbsp;</span>-------------- <=0.5 S<br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;TETRACYCLINE&nbsp;</span>----------   <=1 S<br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;TOBRAMYCIN&nbsp;</span>------------             =>16 R<br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;VANCOMYCIN&nbsp;</span>------------   <=1 S<br>.<br>Blood cultures:<br>[**2181-9-8**] to [**2181-9-15**]: No growth<br>.<br>Urine:<br>[**2181-9-9**]: No growth<br>[**2181-9-20**]: No growth<br>.<br>Stool:<br>[**2181-9-24**]: C. Diff - negative<br>Discharge Labs:<br>.<br>[**2181-9-26**] 05:25AM BLOOD WBC-8.2 RBC-3.03* Hgb-9.5* Hct-25.7*<br>MCV-85 MCH-31.4 MCHC-37.1* RDW-16.6* Plt Ct-179<br>[**2181-9-26**] 05:25AM BLOOD Glucose-118* UreaN-22* Creat-0.7 Na-134<br>K-3.6 Cl-95* HCO3-30 AnGap-13<br>[**2181-9-26**] 05:25AM BLOOD Calcium-8.3* Phos-3.2 Mg-1.6<br><br>Brief Hospital Course:<br>61 y/o M w/ h/o NSCLC s/p RUL lobectomy, severe COPD, recurrent<br>pna over past couple months, with righ sided PNA<br>(MRSA/Pseudomonas) and severe hypoxia requiring significant <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;O2&nbsp;</span><br>suppplementation.<br>.<br>1. PNA with Severe Hypoxia: Had right multilobar PNA with<br>MRSA/Pseudomonas growing from sputum, with WBC count of 9,000<br>and bandemia as high as 22%, elevated anion gap, and elevated<br>lactate to 2.4. Also has poor underlying lung function from COPD<br>(FEV 1.2L in [**2181-7-20**]) and h/o right upper lobe lobectomy.<br>Patient was initially treated with high flow face mask of 15 L<br>at 40% with additional NC with saturations varying from 88 to<br>98%, but with continued frequent coughing which causes<br>desaturations. The patient has since decreased his <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;oxygen&nbsp;</span><br>requirement to <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;Venti amsk&nbsp;</span> at <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;12 lpm&nbsp;</span> with O2 sats rangin 89 to<br>97%. The patient continues to cough and is draining sputum well<br>with transition from dark brown thick sputum to thinner<br>grey/clear sputum. The patient had one episode small volume<br>blood tinged sputum on [**2181-9-24**] attributed to inflammation from<br>underlying PNA. The patient is currently being treated with<br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Linezolid&nbsp;</span> for a planned <span style = \"background-color: #97c4f5; border-radius: 5px;\">&nbsp;21 day&nbsp;</span> course for <span style = \"background-color: #e4e7d2; border-radius: 5px;\">&nbsp;MRSA&nbsp;</span> as well as<br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Ceftazidime&nbsp;</span>, again for a planned <span style = \"background-color: #97c4f5; border-radius: 5px;\">&nbsp;21 day&nbsp;</span> course for <span style = \"background-color: #e4e7d2; border-radius: 5px;\">&nbsp;Pseudomonas&nbsp;</span>.<br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Amikacin&nbsp;</span> was added for syndergy and to <span style = \"background-color: #e4e7d2; border-radius: 5px;\">&nbsp;avoid resistance&nbsp;</span> with a<br>planned <span style = \"background-color: #97c4f5; border-radius: 5px;\">&nbsp;14 day&nbsp;</span> course (ending dates specified on discharge<br>meds). The patient will be discharged with need for  continued<br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;O2&nbsp;</span> suppplementation to keep sats >90% and <94% with <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;O2&nbsp;</span> weaning<br>as possible. The patient will continue to require ongoing Chest<br>PT and physical therapy as well.<br>.<br>2. <span style = \"background-color: #e4e7d2; border-radius: 5px;\">&nbsp;COPD&nbsp;</span>: Has h/o COPD on <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;montelukast&nbsp;</span>, <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;spiriva&nbsp;</span>, <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;advair&nbsp;</span>, <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;flovent&nbsp;</span>,<br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;prednisone&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;10mg&nbsp;</span> at home with PFT's showing FEV of 1.2 L (42%<br>predicted), FEV1/FVC ratio of 42 (59% predicted), 6 L TLC, and<br>elevated Residual Volume (193% predicited). He was given <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Advair&nbsp;</span>,<br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Monteleukast&nbsp;</span>, <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Prednisone&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;60 mg&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;DAily&nbsp;</span> <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;tapered&nbsp;</span> down to <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;30 mg&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;Daily&nbsp;</span><br>as well as <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Atrovent&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;nebulizers&nbsp;</span>. The patient is followed by Dr.<br>[**Last Name (STitle) 14069**], his outpatient pulmonolgist with whom he should continue<br>to be followed after discharge.<br>.<br>3. <span style = \"background-color: #e4e7d2; border-radius: 5px;\">&nbsp;Anxiety&nbsp;</span>: Patient was experiencing a significant amount fo<br>anxiety during this admission, likely at least partly<br>attributable to his air hunger. The patient was maintained on<br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Clonopin&nbsp;</span> with hold parameters with <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Ativan&nbsp;</span> rescues <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;as needed&nbsp;</span>.<br>.<br>4. Acute renal failure: Patient presented with ARF with Cr to<br>2.8 which resolved rapidly with fluids down to baseline of 0.7.<br>.<br>5. <span style = \"background-color: #e4e7d2; border-radius: 5px;\">&nbsp;Chest Pain&nbsp;</span>: Had right sided chest pain, which is diffuse and<br>pleuritic, likely due to PNA. Treated with <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;MSSR&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;45 mg&nbsp;</span> [**Hospital1 **] and <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;IV&nbsp;</span><br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;morphine&nbsp;</span> for <span style = \"background-color: #e4e7d2; border-radius: 5px;\">&nbsp;breakthrough pain&nbsp;</span>.<br>.<br>6. <span style = \"background-color: #e4e7d2; border-radius: 5px;\">&nbsp;Abdominal pain&nbsp;</span>: Patient has been experiencing ongoing<br>abdominal pain for a few days. A KUB showed a non-obstructive<br>bowel gas patterns and the patient's ostomy continues to drain<br>well. The patient has good appetite without Nausea/vomiting. C.<br>Diff was negative x 1. The patient did have an elevated<br>amylase/lipase, now trending down. Pain did not radiate to back<br>and again patient was tolerating PO well without any<br>exacerbation of pain. The patient's symptoms are exacerbated<br>with coughing and are likely secondary to musculoskeletal strain<br>from frequent coughing. Treating pain as above with <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;MS SR&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;45&nbsp;</span> [**Hospital1 **]<br>with rescue doses.<br>.<br>6. Transaminitis: Presented with elevated liver enxymes which<br>trended down to normal. Hepatitis panel negative for Hep B or C.<br><br>.<br>7. H/o LLL nodule and several other areas of focal scarring:<br>should be followed with serial CT scans in the future by<br>outpatient providers.<br>.<br>8. H/o right upper lobe lung ca: Not active currently. Sputum<br>for cytology was negative for malignant cells. No history of<br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;chemo&nbsp;</span> or radiation.<br>.<br>9. H/o <span style = \"background-color: #ff8197; border-radius: 5px;\">&nbsp;thrush&nbsp;</span><span style = \"background-color: #e4e7d2; border-radius: 5px;\">&nbsp;thrush&nbsp;</span>: Likely related to <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;inhaled&nbsp;</span> <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;staeroids&nbsp;</span>. Continued<br>his outpt <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;nystatin&nbsp;</span>.<br>.<br>10. <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Steroid&nbsp;</span> Induced <span style = \"background-color: #ff8197; border-radius: 5px;\">&nbsp;Hyperglycemia&nbsp;</span><span style = \"background-color: #e4e7d2; border-radius: 5px;\">&nbsp;Hyperglycemia&nbsp;</span>: Treated with <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;70/30&nbsp;</span> <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;insulin&nbsp;</span><br>[**Hospital1 **] at <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;AM&nbsp;</span> dose of <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;40&nbsp;</span> and <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;PM&nbsp;</span> dose of <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;22&nbsp;</span>.<br>.<br>11. Anemia: Labs consistant with Anemia of chronic disease. Also<br>was guaiac positive. Needs to be followed in the future. He is<br>s/p colectomy for Ulcerative colitis.<br>.<br>12. Ulcerative colitis: S/P colectomy and ileostomy. Not on any<br>medications for UC.<br>.<br>Code: Full<br>.<br>Communication: wife [**Name (NI) **] (h) [**Telephone/Fax (1) 56560**] (c) [**Telephone/Fax (1) 56561**],<br>daughter [**Name (NI) **] [**Name (NI) 56562**] ([**Telephone/Fax (1) 56563**]<br><br>Medications on Admission:<br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Montelukast&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;10 mg&nbsp;</span> <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;PO&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;DAILY&nbsp;</span><br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Tiotropium Bromide&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;18 mcg&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;DAILY&nbsp;</span><br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Flovent&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;110&nbsp;</span> <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;2&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;puffs&nbsp;</span> [**Hospital1 **]<br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Prednisone&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;10mg&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;daily&nbsp;</span><br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;mucinex&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;600mg&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;tid&nbsp;</span><br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Multivitamin&nbsp;</span> <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;PO&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;DAILY&nbsp;</span><br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Fluticasone-Salmeterol&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;250-50 mcg&nbsp;</span> [**Hospital1 **]<br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Benzonatate&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;100 mg&nbsp;</span> <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;PO&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;TID&nbsp;</span><br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Senna&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;8.6 mg&nbsp;</span> <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;PO&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;BID PRN&nbsp;</span><br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Docusate Sodium&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;100 mg&nbsp;</span> <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;PO&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;BID PRN&nbsp;</span><br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Nexium&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;40 mg&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;twice a day&nbsp;</span>.<br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Morphine&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;30 mg&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Tablet Sustained Release&nbsp;</span> <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;PO&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;Q12H&nbsp;</span><br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;morphine&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;15mg&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;IR&nbsp;</span> <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;PO&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;q8hr PRN&nbsp;</span><br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Nystatin&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;100,000 unit/mL&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Suspension&nbsp;</span> Sig: <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;Five (5) ML&nbsp;</span> <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;PO&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;QID&nbsp;</span><br><br><br>Discharge Medications:<br>1. <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Hexavitamin&nbsp;</span>     <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Tablet&nbsp;</span> Sig: <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;One (1)&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Cap&nbsp;</span> <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;PO&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;DAILY (Daily)&nbsp;</span>.<br>2. <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Fluticasone-Salmeterol&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;250-50 mcg/Dose&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Disk with Device&nbsp;</span> Sig:<br><span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;One (1)&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Disk with Device&nbsp;</span> <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;Inhalation&nbsp;</span> [**Hospital1 **] (<span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;2 times a day&nbsp;</span>).<br>3. <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Nystatin&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;100,000 unit/mL&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Suspension&nbsp;</span> Sig: <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;100,000 MLs&nbsp;</span> <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;PO&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;QID&nbsp;</span><br><span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;(4 times a day)&nbsp;</span>.<br>4. <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Codeine-Guaifenesin&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;10-100 mg/5 mL&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Syrup&nbsp;</span> Sig: <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;5-10 MLs&nbsp;</span> <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;PO&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;Q6H&nbsp;</span><br><span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;(every 6 hours) as needed&nbsp;</span>.<br>5. <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Sodium Chloride&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;0.65&nbsp;</span> % <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Aerosol, Spray&nbsp;</span> Sig: [**11-20**] <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Sprays&nbsp;</span> <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;Nasal&nbsp;</span><br><span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;TID (3 times a day)&nbsp;</span>.<br>6. <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Docusate Sodium&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;100 mg&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Capsule&nbsp;</span> Sig: <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;One (1)&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Capsule&nbsp;</span> <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;PO&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;BID (2&nbsp;</span><br><span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;times a day)&nbsp;</span>.<br>7. <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Lorazepam&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;0.5 mg&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Tablet&nbsp;</span> Sig: <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;1-2&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Tablets&nbsp;</span> <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;PO&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;Q4-6H (every 4 to&nbsp;</span><br><span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;6 hours) as needed&nbsp;</span> for <span style = \"background-color: #e4e7d2; border-radius: 5px;\">&nbsp;anxiety&nbsp;</span>.<br>8. <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Acetylcysteine&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;20&nbsp;</span> % (<span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;200 mg/mL&nbsp;</span>) <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Solution&nbsp;</span> Sig: <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;One (1) ML&nbsp;</span><br>Miscell.  <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;Q4-6H (every 4 to 6 hours) as needed&nbsp;</span>.<br>9. <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Senna&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;8.6 mg&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Tablet&nbsp;</span> Sig: <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;One (1)&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Tablet&nbsp;</span> <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;PO&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;BID (2 times a&nbsp;</span><br><span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;day)&nbsp;</span>.<br>10. <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Montelukast&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;10 mg&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Tablet&nbsp;</span> Sig: <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;One (1)&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Tablet&nbsp;</span> <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;PO&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;DAILY&nbsp;</span><br><span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;(Daily)&nbsp;</span>.<br>11. <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Zolpidem&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;5 mg&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Tablet&nbsp;</span> Sig: <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;One (1)&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Tablet&nbsp;</span> <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;PO&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;HS (at bedtime)&nbsp;</span><br><span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;as needed&nbsp;</span>.<br>12. <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Heparin (Porcine)&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;5,000 unit/mL&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Solution&nbsp;</span> Sig: <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;5000 (5000)&nbsp;</span><br><span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;units&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Injection&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;TID (3 times a day)&nbsp;</span>: Continue until patient is<br>regularly ambulatory, than may D/C.<br>13. <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Pantoprazole&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;40 mg&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Tablet, Delayed Release&nbsp;</span> (E.C.) Sig: <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;One&nbsp;</span><br><span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;(1)&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Tablet, Delayed Release (E.C.)&nbsp;</span> <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;PO&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;Q24H (every 24 hours)&nbsp;</span>.<br>14. <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Ipratropium Bromide&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;0.02&nbsp;</span> % <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Solution&nbsp;</span> Sig: <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;One (1)&nbsp;</span> <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;inhalation&nbsp;</span><br><span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;Inhalation&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;Q4H (every 4 hours) as needed&nbsp;</span>.<br>15. <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Clonazepam&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;0.25 mg&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Tablet, Rapid Dissolve&nbsp;</span> Sig: <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;One (1)&nbsp;</span><br><span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Tablet, Rapid Dissolve&nbsp;</span> <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;PO&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;three times a day&nbsp;</span>: Hold for RR < 16.<br>16. <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Guaifenesin&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;600 mg&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Tablet Sustained Release&nbsp;</span> Sig: <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;Two (2)&nbsp;</span><br><span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Tablet Sustained Release&nbsp;</span> <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;PO&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;BID (2 times a day)&nbsp;</span>.<br>17. <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Morphine&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;15 mg&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Tablet Sustained Release&nbsp;</span> Sig: <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;Three (3)&nbsp;</span><br><span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Tablet Sustained Release&nbsp;</span> <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;PO&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;Q12H (every 12 hours&nbsp;</span>).<br>18. <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Linezolid&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;600 mg/300 mL&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Parenteral Solution&nbsp;</span> Sig: <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;Six Hundred&nbsp;</span><br><span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;(600) mg&nbsp;</span> <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;Intravenous&nbsp;</span>  <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;Q12H (every 12 hours)&nbsp;</span> <span style = \"background-color: #97c4f5; border-radius: 5px;\">&nbsp;for 5 days&nbsp;</span>: First<br>dose: [**2181-9-10**]<br>Continue for total of <span style = \"background-color: #97c4f5; border-radius: 5px;\">&nbsp;21 day&nbsp;</span> course<br>Last dose: [**2181-9-30**].<br>19. <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Ceftazidime-Dextrose (Iso-osm)&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;2 g/50 mL&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Piggyback&nbsp;</span> Sig: <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;Two&nbsp;</span><br><span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;(2) grams&nbsp;</span> <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;Intravenous&nbsp;</span>  <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;Q8H (every 8 hours)&nbsp;</span> <span style = \"background-color: #97c4f5; border-radius: 5px;\">&nbsp;for 7 days&nbsp;</span>: First<br>dose: [**2181-9-12**]<br>Continue for total of <span style = \"background-color: #97c4f5; border-radius: 5px;\">&nbsp;21 day&nbsp;</span> course<br>Last dose: [**2181-10-2**].<br>20. <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Amikacin&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;250 mg/mL&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Solution&nbsp;</span> Sig: <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;One (1) gram&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Injection&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;Q24H&nbsp;</span><br><span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;(every 24 hours)&nbsp;</span> <span style = \"background-color: #97c4f5; border-radius: 5px;\">&nbsp;for 3 days&nbsp;</span>: First dose: [**2181-9-15**]<br>Continue for total <span style = \"background-color: #97c4f5; border-radius: 5px;\">&nbsp;14 day&nbsp;</span> course<br>last dose: [**2181-9-28**].<br>21. <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Dolasetron&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;12.5 mg/0.625 mL&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Solution&nbsp;</span> Sig: <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;12.5 mg&nbsp;</span><br><span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;Intravenous&nbsp;</span>  <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;Q8H (every 8 hours) as needed&nbsp;</span> for <span style = \"background-color: #e4e7d2; border-radius: 5px;\">&nbsp;nausea&nbsp;</span> /<span style = \"background-color: #e4e7d2; border-radius: 5px;\">&nbsp;vomiting&nbsp;</span>.<br><br>22. <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Morphine&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;2 mg/mL&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Syringe&nbsp;</span> Sig: <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;Two (2) mg&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Injection&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;Q4H&nbsp;</span><br><span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;(every 4 hours) as needed&nbsp;</span> for <span style = \"background-color: #e4e7d2; border-radius: 5px;\">&nbsp;breakthrough pain&nbsp;</span>.<br>23. <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Prednisone&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;10 mg&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Tablet&nbsp;</span> Sig: <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;Three (3)&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Tablet&nbsp;</span> <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;PO&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;DAILY&nbsp;</span><br><span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;(Daily)&nbsp;</span>: Continue <span style = \"background-color: #97c4f5; border-radius: 5px;\">&nbsp;for 1 week&nbsp;</span>. Wean as possible over following 2<br>to 3 weeks to <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;10mg&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;daily&nbsp;</span> as possible.<br>24. <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Insulin NPH-Regular Human Rec&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;100 unit/mL (70-30)&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Suspension&nbsp;</span><br>Sig: see instructions units <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;Subcutaneous&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;once a day&nbsp;</span>: Please<br>provide <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;40 units&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;qam&nbsp;</span><br><span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;22 units&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;qhs&nbsp;</span>.<br>25. <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Insulin Lispro (Human)&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;100 unit/mL&nbsp;</span> <span style = \"background-color: #7aecec; border-radius: 5px;\">&nbsp;Solution&nbsp;</span> Sig: <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;One (1)&nbsp;</span><br><span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;unit&nbsp;</span> <span style = \"background-color: #ffeb80; border-radius: 5px;\">&nbsp;Subcutaneous&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;four times a day&nbsp;</span>: Please provide <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Humalog&nbsp;</span><br><span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;sliding scale&nbsp;</span> <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;with meals&nbsp;</span> and <span style = \"background-color: #9cc9cc; border-radius: 5px;\">&nbsp;at bedtime&nbsp;</span> per provided <span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;sliding&nbsp;</span><br><span style = \"background-color: #bfe1d9; border-radius: 5px;\">&nbsp;scale&nbsp;</span> in addition to standing <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Insulin&nbsp;</span> <span style = \"background-color: #ff9561; border-radius: 5px;\">&nbsp;70/30&nbsp;</span> .<br><br><br>Discharge Disposition:<br>Extended Care<br><br>Facility:<br>[**Hospital3 105**] Northeast - [**Location (un) 701**]<br><br>Discharge Diagnosis:<br>Primary:<br>MRSA/Pseudomonas Pneumonia<br>COPD exacerbation<br>Abdominal Pain<br><span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;Steroid&nbsp;</span> induced <span style = \"background-color: #ff8197; border-radius: 5px;\">&nbsp;hyperglycemia&nbsp;</span><br>Anxiety<br>.<br>Secondary:<br>History of Non small cell Lung Ca s/p pneumonectomy<br>Ulcerative Colitis<br>Anemia<br><br><br>Discharge Condition:<br>Fair. Patient with ongoing <span style = \"background-color: #aa9cfc; border-radius: 5px;\">&nbsp;O2 requirement&nbsp;</span> above baseline.<br>Symptomatically improved, hemodynamically stable.<br><br><br>Discharge Instructions:<br>1. Please take all medications as prescribed<br>.<br>2. please keep all outpatient appointments<br>.<br>3. Please return to the hospital for symptoms fevers/chills,<br>worsening respiratory status, shortness of breath, chest pain,<br>or any other concerning symptoms<br><br>Followup Instructions:<br>1. Please follow up with your PCP, [**Last Name (NamePattern4) **]. [**Last Name (STitle) **] on discharge. Please<br>call his office at [**Telephone/Fax (1) 36558**] to make an appointment<br>.<br>2. Please follow up with your Pulmonologist within one week of<br>discharge from your rehab facility. Please call his office to<br>schedule an appointment.<br><br><br><br>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "utils.display_ehr(ehr[0], tags[0])"
   ]
  }
 ],
 "metadata": {
  "colab": {
   "name": "Preprocessing_v2.ipynb",
   "provenance": []
  },
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.8.3"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 1
}
